Throughout the legislative battle over health care reform, health care stocks underachieved. The uncertainty over how health sub-segments might be affected – devices, providers, “Big Pharma,”... read more »

This article originally appeared on sharkbiotech.com.  When the market sells off like it has this month everything gets killed and there is little regards to fundamentals. In the case of DEPO we... read more »

This medical device maker should receive an FDA approval later this year despite some recent concerns.
 This article first appeared on July 28 on SharkBiotech.com. EW is a medical device... read more »

As the array of ETF product offerings has expanded in recent years, the biotech space has seen significant activity. Currently, there are five biotech ETFs that have accumulated nearly $3.5 billion... read more »

On Jim's Notes last week I discussed the issue of the leadership in the broad markets as a challenge. I am seeing money rotate into the defensive sectors over the last 3-4 weeks. If we looked at... read more »